La vendita allo scoperto per Sensei Biotherapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Sensei Biotherapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Sensei Biotherapeutics (NASDAQ:SNSE) Azioni, Report sulle vendite allo scoperto

Sensei Biotherapeutics

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

WIIM

Clearwater Paper shares are trading higher. RBC Capital reiterated an Outperform rating on the stock.

ICHR

Ichor Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates. Also. B. Riley Securities raised its price target on the stock from $36 to $38.

INGR

Ingredion shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and raised its FY24 adjusted EPS guidance above estimates.

Piper Sandler analyst Adam Maeder reiterates Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and raises the price target from $255 to $260.

News

Price Target

Reiteration

Analyst Ratings

INSP

Piper Sandler Reiterates Overweight on Inspire Medical Systems, Raises Price Target to $260

RBC Capital analyst Conor McNamara maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and raises the price target from $86 to $89.

HOLX

RBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89

AOSL

Alpha & Omega shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. B. Riley Securities lowered its price target on the stock from $50 to $47.

Mark Cuban is an outspoken billionaire and part-owner of the Dallas Mavericks but also one of the most vocal critics of the former president. He has used terms like &#8220;fascist&#8221; to describe Trump&#8217;s behavior. However, Cuban was recently seen on ABC justifying his business relationship with Miriam Adelson, who gave Trump an astounding $100 million to support his 2024 election campaign.
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Adelson&#8217;s hefty donation to Trump – the largest of any sports team owner – shows she's all-in on Trump's campaign. That has made things somewhat awkward for Cuban, considering his loud and clear support for Kamala Harris, who is running against Trump.
Yet, when asked how he felt about this partnership, Cuban brushed off the issue. &#8220;Do you know how everyone is voting who you work with? Do you know how the owners of your company are voting? This is America. People get to choose their candidates and vote for who they want, which makes it amazing,&#8221; Cuban said in an interview. Cuban&#8217;s message is that differing political views shouldn't interfere with running a business.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Cuban also pointed out that he's not giving money to Harris – or any other political candidate, for that matter. Despite his <a href="https://www.benzinga.com/news/24/09/40745014/kamala-harris-is-pro-business-mark-cuban-says-vice-presidents-centre-100-policies-differ-from-bidens">vocal support for the current vice president</a>, Cuban hasn&#8217;t donated a penny to her campaign. He believes in making a difference through his words and influence instead of writing checks.
He's been on social media defending Harris and has engaged in fiery debates, <a href="https://www.benzinga.com/markets/equities/24/10/41568486/mark-cuban-highlights-trumps-potential-to-ruin-christmas-but-he-might-also-end-up-spoiling-the-p">calling out Trump's behavior</a> as dangerous and out of touch. Cuban also stated in the same ABC interview that &#8220;Donald Trump is not a normal candidate,&#8221; claiming that he has used divisive language and taken actions that, in Cuban&#8217;s opinion, verge on authoritarianism.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
Despite clashing ideologies, Cuban seems comfortable keeping his business relationships and political beliefs separate. Miriam Adelson, who inherited a vast fortune from her late husband Sheldon Adelson, now <a href="https://www.benzinga.com/news/23/12/36231225/mark-cuban-to-retain-25-stake-in-dallas-mavericks-after-sale-to-adelson-family-report">shares ownership of the Mavericks with Cuban</a>. The Adelson family is deeply involved in politics and their support of Trump hasn't wavered. On the other hand, Cuban is sticking to his guns – supporting Harris in the media and making the case for what he believes is best for the country.
At the end of the day, Cuban seems determined to stay true to his political convictions and his business partnerships. &#8220;This is America,&#8221; he says – a place where people can disagree, even sharply and still find ways to work together.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Startups

'This Is America,' Mark Cuban Says, Justifying His Business Relationship With Trump's $100M Megadonor And Mavericks Co-Owner

<a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-">Kevin O'Leary</a>, best known from Shark Tank, has backed Elon Musk's sweeping $2 trillion plan to slash federal spending. With former President Donald Trump's backing, Musk is proposed to head the Department of Government Efficiency (DOGE) if Trump secures a second term.&nbsp;
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
O'Leary enthusiastically remarked on Fox News, "Release the hounds" about unleashing Musk's cost-cutting skills across federal agencies. "Let them in there and come back with a shopping list of ideas and let's debate it. Why not? We need to find some savings."
In O'Leary's view, the U.S. federal government is "the biggest business in America." He sees Musk, the mind behind Tesla and SpaceX, as uniquely equipped to tackle this budget behemoth.&nbsp;
"Who has the executional skills and the track record to even look at this problem?" he said, emphasizing that Musk's focus and determination make him an ideal candidate. Indeed, O'Leary believes that Musk's efficiency ethos, which has driven companies like SpaceX to success, would transfer seamlessly to federal budget cuts – an area few entrepreneurs would tread.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Musk has clarified that he views today's government spending as unsustainable, especially with national debt interest payments now outstripping the defense budget.&nbsp;
Speaking at a Trump rally, he linked federal spending to inflation and increased taxes, which he warned are squeezing <a href="https://www.benzinga.com/personal-finance/24/08/40582239/californias-new-plan-taxpayers-might-soon-be-funding-home-loans-for-illegal-migrants-heres-what-">taxpayers </a>dry. With his proposal to shave off $2 trillion, Musk aims to start the work he sees as vital for long-term economic stability.
But this grand vision has detractors. Some experts question whether cutting a third of federal spending is possible without compromising essential services.&nbsp;
Analysis from the Washington Post noted that Musk&#8217;s cuts could gut programs like health care, food security and housing, impacting millions of Americans. Even previously untouchable sectors, such as Social Security and the military, may be affected.&nbsp;
See Also: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Musk acknowledged on X (formerly Twitter) that his proposed cuts could result in economic turmoil, suggesting that hard times would be ahead before any benefits emerged.
Still, O'Leary remains undeterred. He sees Musk's focus as an asset, contrasting the entrepreneur's "100% signal" approach with what he describes as other business leaders' focus on "noise." To O'Leary, Musk's dedication to his projects means he is all about the mission and not distracted by side issues, making him ideal for leading such a challenging initiative.&nbsp;
He even suggested that Musk go beyond the $2 trillion target. "We've got to go find $2 trillion; we've got to go find $5 trillion," O'Leary urged.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Kevin O'Leary Supports Elon Musk's $2 Trillion Plan To Slash Government Spending With Trump's Backing–'It's Time To Release The Hounds'

COGT

Cogent Biosciences shares are trading lower after the company announced Bezuclantinib presentations at the 66th annual American Society of Hematology meeting.

RBC Capital analyst Sean Dodge reiterates IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and maintains $270 price target.

RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Outperform and raises the price target from $352 to $359.

Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Raises Price Target to $359

PRAA

PRA Group shares are trading higher after the company reported better-than-expected Q3 financial results. Additionally, Truist Securities maintained a Buy rating on the stock and raised its price target from $28 to $31.

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith reiterates Root (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) with a Outperform and raises the price target from $82 to $90.

ROOT

Keefe, Bruyette & Woods Reiterates Outperform on Root, Raises Price Target to $90

CENX

Century Aluminum shares are trading higher after the company reported better-than-expected Q3 financial results and B.Riley Securities raised its price target on the stock from $22 to $24.

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $510 to $503.

VRTX

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $503

Diversified Healthcare Trust shares are trading lower after the company reported worse-than-expected Q3 financial results.

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Market Perform and lowers the price target from $210 to $198.

Keefe, Bruyette & Woods Maintains Market Perform on Meritage Homes, Lowers Price Target to $198

JP Morgan analyst Peter Peng maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Overweight and lowers the price target from $150 to $135.

SLAB

JP Morgan Maintains Overweight on Silicon Laboratories, Lowers Price Target to $135

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and raises the price target from $252 to $254.

ILMN

RBC Capital Maintains Outperform on Illumina, Raises Price Target to $254

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Market Perform and lowers the price target from $6 to $5.

Keefe, Bruyette & Woods Maintains Market Perform on Marqeta, Lowers Price Target to $5

LIDR, HOOK and BCAB among mid-day movers

Sensei stock plunges 46% in wake of Phase 1 data

An update from Sensei Biotherapeutics (SNSE) is now available. Sensei Biotherapeutics, Inc. has refreshed its corporate presentation, revealing it ...

Sensei Biotherapeutics Unveils Updated Corporate Presentation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sensei Biotherapeutics (SNSE – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sensei Biotherapeutics (SNSE – Research Report) and ...

Analysts Are Bullish on These Healthcare Stocks: Sensei Biotherapeutics (SNSE), Viking Therapeutics (VKTX)

Sensei Biotherapeutics (SNSE) has shared an announcement. Dr. Jessie English has announced her resignation from the Board of Directors at Sensei Bi...

Dr. Jessie English Resigns from Sensei Biotherapeutics Board

Sensei Biotherapeutics GAAP EPS of -$0.28

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) just reported results for the second quarter of 2024.<ul><li>Sensei Biotherapeutics reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snse-stock-earnings-sensei-biotherapeutics-for-q2-of-2024/">SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNSE Stock Earnings: Sensei Biotherapeutics Beats EPS for Q2 2024

Sensei Biotherapeutics (SNSE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White ...

Buy Rating Affirmed for Sensei Biotherapeutics on Strong Financials and Promising Drug Trials

Sensei Biotherapeutics ( ($SNSE) ) just unveiled an announcement. Sensei Biotherapeutics, Inc. recently appointed Josiah Craver as their new princi...

Sensei Biotherapeutics Appoints New Financial Chief

AKAN

BCAB

GNLX

HOOK

ISSC

LICN

LIDR

LUCY

MRUS

NCPL

OKLO

OMER

ONMD

REGN

RNAZ

SMMT

SNSE

SWIN

TLSI

TROO

VKTX

VSTM

Press Releases

General

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Comments

Sensei Biotherapeutics

Vendite allo scoperto

Sensei Biotherapeutics (NASDAQ:SNSE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO